The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA,
MicroStrategy (NASDAQ:MSTR) has outperformed the market over the past 20 years by 9.86% on an annualized basis producing an average annual return of 17.6%. Currently, MicroStrategy has a market capitalization of $2.75 billion.